Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
54.73
-0.06 (-0.11%)
May 29, 2026, 4:00 PM EDT - Market closed
Xenon Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 545.87 | 199.16 | 142.71 | 148.64 | 57.24 | 175.69 |
Short-Term Investments | 548.88 | 349.72 | 484.19 | 489.44 | 534.85 | 376.09 |
Cash & Short-Term Investments | 1,095 | 548.89 | 626.91 | 638.08 | 592.09 | 551.77 |
Cash Growth | 99.18% | -12.45% | -1.75% | 7.77% | 7.31% | 211.74% |
Accounts Receivable | - | - | - | 0.87 | 0.99 | 2.77 |
Other Receivables | 1.17 | 1.37 | 1.47 | - | - | - |
Total Trade Receivables | 1.17 | 1.37 | 1.47 | 0.87 | 0.99 | 2.77 |
Other Current Assets | 10.72 | 10.39 | 6.89 | 6.01 | 7.23 | 4.48 |
Total Current Assets | 1,107 | 560.65 | 635.26 | 644.96 | 600.3 | 559.02 |
Net Property, Plant & Equipment | 14.58 | 15.35 | 18.22 | 18.85 | 16.91 | 12.52 |
Long-Term Investments | 244.87 | 37.15 | 127.5 | 292.79 | 128.68 | - |
Other Long-Term Assets | 20.72 | 20.02 | 17.16 | 8.2 | 8.26 | 0.47 |
Total Assets | 1,387 | 633.16 | 798.14 | 964.8 | 754.15 | 572.01 |
Accounts Payable | 38.25 | 40.26 | 34.22 | 25.97 | 22.21 | 13.72 |
Current Portion of Leases | 1.56 | 1.53 | 1.37 | 1.3 | 0.49 | 0.61 |
Total Current Liabilities | 39.82 | 41.79 | 35.59 | 27.27 | 22.7 | 14.32 |
Long-Term Leases | 5.93 | 6.41 | 7.65 | 9.6 | 9.95 | 7.65 |
Other Long-Term Liabilities | 3.25 | 3.2 | - | - | - | - |
Total Long-Term Liabilities | 9.18 | 9.61 | 7.65 | 9.6 | 9.95 | 7.65 |
Total Liabilities | 48.99 | 51.4 | 43.24 | 36.88 | 32.65 | 21.97 |
Preferred Stock | - | - | - | - | - | 7.73 |
Common Stock | 2,422 | 1,599 | 1,457 | 1,436 | 1,065 | 783.17 |
Additional Paid-in Capital | 264.88 | 228.23 | 199.15 | 156.76 | 142.11 | 117.5 |
Accumulated Other Comprehensive Income | -1.21 | 0.34 | -1.61 | -0.08 | -3 | -0.99 |
Retained Earnings | -1,348 | -1,245 | -899.47 | -665.14 | -482.75 | -357.37 |
Shareholders' Equity | 1,338 | 581.76 | 754.9 | 927.92 | 721.5 | 550.03 |
Total Liabilities & Equity | 1,387 | 633.16 | 798.14 | 964.8 | 754.15 | 572.01 |
Total Debt | 7.49 | 7.94 | 9.02 | 10.9 | 10.44 | 8.26 |
Net Cash (Debt) | 1,087 | 540.94 | 617.89 | 627.18 | 581.65 | 543.52 |
Net Cash Growth | 100.99% | -12.45% | -1.48% | 7.83% | 7.02% | 212.94% |
Net Cash Per Share | 13.35 | 6.83 | 7.93 | 9.38 | 9.61 | 12.46 |
Book Value | 1,338 | 581.76 | 754.9 | 927.92 | 721.5 | 550.03 |
Book Value Per Share | 16.43 | 7.34 | 9.69 | 13.87 | 11.92 | 12.61 |
Tangible Book Value | 1,338 | 581.76 | 754.9 | 927.92 | 721.5 | 550.03 |
Tangible Book Value Per Share | 16.43 | 7.34 | 9.69 | 13.87 | 11.92 | 12.61 |